Daré Bioscience receives new U.S. patent for HPV treatment program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Daré Bioscience receives new U.S. patent for HPV treatment program

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

September 28, 2026 8:20 AM EDT

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award

DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently no FDA-approved pharmacologic treatment

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.... More